Q-omics provides the consensus-scored WLS profile across patient tissues and cancer cell-line models. WLS expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, WLS is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, WLS RNA expression shows 19,136 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where WLS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WLS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WLS survival associations across molecular data types. WLS RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WLS RNA expression–survival associations across cancer types. High WLS expression shows unfavorable associations in ACC, BLCA, HNSC and LGG, but favorable associations in KIRC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for WLS RNA expression.
This table summarizes WLS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for WLS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WLS shows lower tumor expression in KIRC, KIRP, BLCA, THCA, READ and COAD. The KIRC box plot shows higher WLS RNA expression in normal versus tumor tissue (log2 FC = −1.672, t-test p < 0.001).
This table shows molecular features associated with WLS in patient tissues and cancer cell lines. In patient samples, WLS shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, WLS RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
